CANFOUR clinical results, interview

Cantargia listed on Nasdaq Stockholm (Small Cap)

Two Nobel Prizes with utmost significance for Cantargia’s research

The new generation of cancer treatments

Cantargia's CAN04 antibody treatment fights cancer by activating the immune system, and by blocking signals that lead to tumour growth.

Development of new antibody-based cancer treatments

Cantargia is a biotechnology company specialising in dual-action antibody-based cancer treatments. CAN04, the company's patented antibody treatment, has a dual-action and fights cancer by activating the immune system and by blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immunoncology.

Cantargia is since September 25, 2018 listed on Nasdaq Stockholm main market (Small Cap).

(R) Cantargia publishes interim report for third quarter of 2018

Cantargia AB’s interim report for the third quarter of 2018 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.

30/10/2018

(R) Cantargia AB: Nomination Committee appointed ahead of 2019 Annual General Meeting

Cantargia AB (publ) hereby provides notification that the Nomination Committee has been appointed ahead of the 2019 Annual General Meeting, and consists of Sten Verland (...

20/10/2018

(R) Cantargia presented positive phase I clinical data with lead candidate CAN04 at ESMO

· The antibody CAN04 was well tolerated and 6 mg/kg is a safe dose · Effects on biomarkers and 5 of 13 evaluable patients achieved stable disease · 10 mg/kg curren...

09/10/2018

(R) Cantargia presents clinical data from its ongoing CANFOUR trial at ESMO

Cantargia AB (publ) today announced that interim results from its clinical Phase I/II trial of lead candidate CAN04 (nidanilimab) will be presented in a poster presentati...

01/10/2018

(R) Cantargia obtains patent in USA for the antibody CAN03

Cantargia AB today announces that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application 15/501,710 directed to the antibody C...

19/09/2018